Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 66
Filter
1.
Arch Pediatr ; 29(4): 258-262, 2022 May.
Article in English | MEDLINE | ID: mdl-35304031

ABSTRACT

OBJECTIVE: The use of proton pump inhibitors has increased exponentially over the past 20 years. Several side effects have been reported and concerns exist about the consequences of long-term proton pump inhibitors on health, leading to limitation of their use. The present study analyzed prescriptions of proton pump inhibitors at inpatient units and assessed their compliance with current recommendations. METHODS: This single-center, observational, retrospective study reviewed medical file of patients hospitalized at the pediatric medical departments of the Bordeaux University Hospital between April 1 and September 30, 2019. Patients younger than 18 years, hospitalized in the pediatric hospital units and treated with proton pump inhibitors were included. Prescriptions of proton pump inhibitors were compared with French and international guidelines. RESULTS: Proton pump inhibitors were prescribed for 251 of 2237 children (11%), mainly for gastroesophageal reflux disease (47%) and prevention of peptic ulcer disease (32.7%). Proton pump inhibitor prescription complied to recommendations in 34.5% of cases, less often in children aged younger than 1 year (13.5%) than in older children. Compliance to recommendations was lower when proton pump inhibitors were indicated for the prevention of peptic disease (5%) than for gastroesophageal reflux disease (48%). CONCLUSIONS: Proton pump inhibitors are frequently prescribed for hospitalized children, and indications comply with recommendations in only 35% of the cases. Efforts in spreading awareness of the recommendations on the use of proton pump inhibitors in children are mandatory among hospital pediatricians.


Subject(s)
Gastroesophageal Reflux , Proton Pump Inhibitors , Child , Child, Hospitalized , Gastroesophageal Reflux/drug therapy , Hospitals, University , Humans , Inappropriate Prescribing , Proton Pump Inhibitors/adverse effects , Retrospective Studies
2.
Arch Pediatr ; 27(4): 202-205, 2020 May.
Article in English | MEDLINE | ID: mdl-32278587

ABSTRACT

In France, human milk banks are in charge of the collection, analysis, processing, and distribution of human milk to neonatology centers for preterm infants. Knowledge of what motivates mothers to donate their milk could lead to better communication regarding human milk donation. A satisfaction survey was conducted among mothers who were donating their milk to a human milk bank. In total, 214 mothers answered a questionnaire in the presence of the collector during a home visit. The median age of the mothers was 31 years (18-46), mainly high school (19%) or university (65%) graduates, and the median duration of donation was 3 months (0.5-22). At the time of the study, the median age of infants was 3 months (0.5-25), and 88% of infants were exclusively breastfed. About three quarters of mothers were motivated by willingness to help others, a quarter of them being especially sensitive to premature neonatal care; 30% of mothers were motivated by having a high supply of milk. Around 25% of mothers were given information on human milk donation during pregnancy, and two thirds after delivery, mainly by the maternity ward midwives (53.4%) or by collectors during their visit (14.1%). Most mothers (72%) found the human milk donation process easy and most of them (92.5%) were willing to donate their milk again after their next pregnancy. This survey shows that more than 90% of mothers are satisfied with donation to human milk banks. However, efforts should be made to provide information on breastfeeding and human milk donation to the general population and health professionals.


Subject(s)
Health Knowledge, Attitudes, Practice , Milk Banks , Milk, Human , Mothers/psychology , Motivation , Personal Satisfaction , Tissue Donors/psychology , Adolescent , Adult , Female , France , Humans , Middle Aged , Surveys and Questionnaires , Young Adult
3.
Diabetes Metab ; 46(3): 219-222, 2020 06.
Article in English | MEDLINE | ID: mdl-31325500

ABSTRACT

AIM: While serum fructosamine may be a good marker of glucose control in pregnant women with diabetes, its relationship with macrosomia is still uncertain. METHODS: In 130 hyperglycaemic women with singleton pregnancies (117 gestational diabetes mellitus, 13 pregestational diabetes), serum fructosamine and HbA1c levels were measured at 25±7 weeks of gestation. Levels in mothers of infants with and without macrosomic newborns (birth weight>4000g and/or large-for-gestational-age birth weight>90th percentile) were compared using logistic regression analysis adjusted for macrosomia risk factors. RESULTS: These 130 pregnant women were 33±5 years old; their BMI before pregnancy was 27.7±6.9kg/m2, and they gained 7.5±5.1kg during the first 6 months of gestation. Glucose control was good according to HbA1c levels (5.3±0.3%; 34±2mmol/mol), yet 17/130 (13%) newborns had macrosomia: 3900±227g vs 3057±512g (P<0.001) in the others. These mothers were older and had higher parity, whereas their BMI scores before pregnancy and gestational weight gains did not differ. Fructosamine levels were also higher at 221±40µmol/L vs 192±22µmol/l (P<0.001), respectively, and remained significant even after adjusting for maternal age, BMI, parity, type of diabetes, antecedents of macrosomia and excessive gestational weight gain. By contrast, HbA1c did not differ between the two groups. In fact, nearly two-thirds (64.7%) of the mothers of macrosomic newborns had fructosamine levels>200µmol/l vs 31.9% of mothers with non-macrosomic newborns (P<0.05). CONCLUSION: High fructosamine levels are associated with macrosomia in the newborns of well-controlled hyperglycaemic pregnant women.


Subject(s)
Diabetes, Gestational/blood , Fetal Macrosomia/diagnosis , Fructosamine/blood , Hyperglycemia/blood , Pregnancy Complications/blood , Adult , Cross-Sectional Studies , Female , Fetal Macrosomia/blood , Humans , Pregnancy
4.
Eur J Clin Nutr ; 70(4): 528-31, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26695725

ABSTRACT

BACKGROUND/OBJECTIVES: The objective of this disease was to determine the prevalence of malnutrition in children with congenital heart disease (CHD). SUBJECTS/METHODS: A total of 125 children with CHD, under 6 months of age, were divided into four groups: no pulmonary hypertension (PH) or cyanosis (group 1, n=47), isolated cyanosis (group 2, n=52), isolated PH (group 3, n=16), and PH and cyanosis (group 4, n=10). Six children died at 6 months (n=4), 12 months (n=1) and 19 months (n=1). The remaining children were followed-up for 24 months. Prevalence of moderate to severe malnutrition (weight/weight for height <80%), caloric intake and medications were compared between the four groups. RESULTS: Moderate or severe malnutrition was more frequent in group 4 (100%) compared with others groups (group 1, 20%; group 2, 16.7% and group 3, 50%; P<0.05). Low oral caloric intake was more frequent in group 3 (71.4%) and group 4 (75%) than in group 1 (28%) and 2 (28.6%) (P<0.05). Food enrichment was practised in half of the children of group 4 and rarely in other groups (group 1, 15.8%; group 2, 8.6% and group 3, 11.1%; P<0.05). Enteral feeding was used more often in groups 3 (33.3%) and 4 (50%) than in groups 1 (15.8%) or 2 (14.3%; P<0.05). CONCLUSIONS: Moderate or severe malnutrition is present in 15% of children with CHD, and it is more frequent in case of PH. Half of these children demonstrate low caloric intake, whereas few have proper nutritional support.


Subject(s)
Heart Defects, Congenital/therapy , Nutritional Status , Protein-Energy Malnutrition/epidemiology , Body Mass Index , Body Weight , Child, Preschool , Energy Intake , Enteral Nutrition , Female , Follow-Up Studies , Heart Defects, Congenital/complications , Humans , Infant , Longitudinal Studies , Male , Prevalence , Protein-Energy Malnutrition/etiology , Protein-Energy Malnutrition/therapy , Retrospective Studies , Risk Factors
5.
Rev Mal Respir ; 32(6): 566-85, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26001957

ABSTRACT

INTRODUCTION: The gastrointestinal tract is a major source of morbidity in adults with cystic fibrosis (CF), with a wide range of complications, some of them being specific to the underlying disease. STATE OF KNOWLEDGE: Abnormal CFTR function, with reduced bicarbonate and other ion transport levels through the apical surface of epithelial cells, affects the intestinal tract including the pancreas and the liver. Similarly to what is observed in the respiratory tract, gastrointestinal CFTR dysfunction leads to mucus accumulation, dysmotility, small bowel bacterial overgrowth and inflammation with alteration of innate immune responses, all of which being likely to be interrelated. In developed countries, almost half of patients with CF are adults followed in multidisciplinary CF care centres by pneumologists who often have to manage gastrointestinal complications. CONCLUSION: It therefore appears essential that adult gastroenterologists develop the expertise needed for managing CF gastrointestinal complications in close collaboration with multidisciplinary CF care centre teams to improve the quality of life of adults with CF.


Subject(s)
Cystic Fibrosis/complications , Cystic Fibrosis/therapy , Gastrointestinal Diseases/therapy , Liver Diseases/therapy , Pancreatic Diseases/therapy , Adult , Biliary Tract Diseases/epidemiology , Biliary Tract Diseases/etiology , Biliary Tract Diseases/therapy , Cystic Fibrosis/epidemiology , Gastrointestinal Diseases/epidemiology , Gastrointestinal Diseases/etiology , Humans , Liver Diseases/epidemiology , Liver Diseases/etiology , Neoplasms/epidemiology , Neoplasms/etiology , Neoplasms/therapy , Pancreatic Diseases/epidemiology , Pancreatic Diseases/etiology
6.
Arch Pediatr ; 21(11): 1200-5, 2014 Nov.
Article in French | MEDLINE | ID: mdl-25267194

ABSTRACT

UNLABELLED: The aim of this study was to analyze why anti-rotavirus vaccination is rarely used in France, although this infection is frequent and associated with a large number of hospitalizations. METHOD: A questionnaire was sent to 732 general practitioners and pediatricians in the Bordeaux area. RESULTS: The response rate was 57% (381 GPs and 38 pediatricians). Most of them (71.8%) declared that they received information on the vaccination and more than 80% of them feel that gastroenteritis is a severe disease. However, anti-rotavirus is never prescribed by the majority of them (59.6%) and only 2.6% prescribe it systematically. The reasons are that the patient is not refunded (64.2%), the vaccination timetable is overloaded (53.6%), and there are no recommendations for this vaccination (35.1%). Physicians believe that parents feel gastroenteritis as a benign disease (52.6%) and say that they refuse the vaccination because it is not refunded (77.7%), not mandatory (45.5%), or may have side effects (44.1%). Physicians' prescription of vaccination is correlated to their information on the vaccination and their feeling about the disease's severity. They would modify their practice if the vaccination was recommended and/or refunded. CONCLUSION: The main obstacles against anti-rotavirus vaccination are the absence of recommendations and refunding. The recent recommendation for the vaccination and a lower price should lead to its generalization in France.


Subject(s)
Attitude of Health Personnel , Diarrhea, Infantile/immunology , Diarrhea, Infantile/prevention & control , Gastroenteritis/immunology , Gastroenteritis/prevention & control , Practice Patterns, Physicians' , Rotavirus Infections/immunology , Rotavirus Infections/prevention & control , Rotavirus Vaccines/administration & dosage , Rotavirus Vaccines/immunology , Child, Preschool , Cost-Benefit Analysis , Cross-Sectional Studies , Diarrhea, Infantile/economics , Diarrhea, Infantile/epidemiology , Female , Financing, Personal/economics , France , Gastroenteritis/economics , Gastroenteritis/epidemiology , General Practice/economics , Health Surveys , Hospitalization/economics , Humans , Immunization Schedule , Infant , Male , Pediatrics/economics , Reimbursement Mechanisms/economics , Rotavirus Infections/economics , Rotavirus Infections/epidemiology , Rotavirus Vaccines/economics , Surveys and Questionnaires
8.
Arch Pediatr ; 20(11): 1206-1211, 2013 Nov.
Article in French | MEDLINE | ID: mdl-24080040

ABSTRACT

The outcome of cow milk allergy (CMA) usually progresses to acquisition of tolerance, allowing a normal diet. This study conducted in France aimed to survey practices of milk reintroduction after an exclusion diet. A questionnaire was sent to 278 pediatric centers, exploring the reintroduction procedure in the 3 main types of CMA and in patients with persistent allergy. The response rate was 27%, 53% for tertiary centers and 23% for secondary centers. Cow's milk is reintroduced at a median age of 12months, and after 6months of exclusion diet whatever the type of allergy. In about half the centers, Prick-Tests and specific IgE are tested before milk reintroduction, but the procedure in case of a positive test differs between centers. Procedures are similar regarding the type of milk, the quantity, the place (home or hospital), the presence of an intravenous line, and the time before a second reintroduction. A desensitization procedure is proposed in 43% of centers in case of persistent allergy, after 2 reintroduction failures, and at a median age of 2.5years. Milk reintroduction procedures are similar to those for oral challenge for the diagnosis of CMA but with differences between centers.


Subject(s)
Milk Hypersensitivity/immunology , Milk Proteins/adverse effects , Milk/adverse effects , Practice Patterns, Physicians'/statistics & numerical data , Animals , Child , Child, Preschool , France , Humans , Immunoglobulin E/blood , Infant , Pediatrics , Skin Tests/statistics & numerical data , Surveys and Questionnaires
10.
Pathol Biol (Paris) ; 61(2): e1-4, 2013 Apr.
Article in French | MEDLINE | ID: mdl-21616605

ABSTRACT

Celiac disease is an autoimmune disorder induced by gluten in genetically susceptible individuals. Patients may present with typical symptoms of enteropathy with diarrhoea and failure to thrive, but atypical symptoms, or even silent forms are more often recognized since serologic markers are available. This progress led to the increase of the incidence of the celiac disease during the last 30 years, which reflect probably the improvement in diagnosing atypical forms of the disease. The prevalence is comparable from a country to another, around 0,7 to 2%. There is a progression with time from latent to silent form, and then to the active disease. The exclusion of the gluten from the diet leads to the regression from the active to the latent form of the disease.


Subject(s)
Autoimmune Diseases/epidemiology , Celiac Disease/epidemiology , Glutens/adverse effects , Autoimmune Diseases/etiology , Celiac Disease/etiology , Disease Progression , Glutens/immunology , Humans , Incidence , Models, Biological , Prevalence
11.
Pathol Biol (Paris) ; 2011 Jul 05.
Article in French | MEDLINE | ID: mdl-21733641
13.
Gastroenterol Clin Biol ; 33(1 Pt 1): 31-40, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19118966

ABSTRACT

AIM: This study aimed to test the efficacy of mesalazine in maintaining remission in pediatric Crohn's disease (CD) following successful flare-up treatment. METHODS: In this double-blind, randomized, placebo-controlled trial, 122 patients received either mesalazine 50mg/kg per day (n=60) or placebo (n=62) for one year. Treatment allocation was stratified according to flare-up treatment (nutrition or medication alone). Recruitment was carried out over two periods, as the first period's results showed a trend favoring mesalazine. Relapse was defined as a Harvey-Bradshaw score more than or equal to 5. Time to relapse was analyzed using the Cox model. RESULTS: The one-year relapse rate was 57% (n=29) and 63% (n=35) in the mesalazine and placebo groups, respectively. We demonstrated a twofold lower relapse risk (P<0.02) in patients taking mesalazine in the medication stratum (first recruitment period), and a twofold higher risk in patients taking mesalazine in the nutrition stratum (second recruitment period), compared with the other groups. None of the children's characteristics, which differed across the two recruitment periods, accounted for the between-period variation in mesalazine efficacy. One serious adverse event was reported in each treatment group. CONCLUSION: Overall, mesalazine does not appear to be an effective maintenance treatment in pediatric CD.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Crohn Disease/drug therapy , Mesalamine/therapeutic use , Child , Double-Blind Method , Female , Humans , Male , Secondary Prevention , Treatment Outcome
15.
Ann Dermatol Venereol ; 135(3): 222-4, 2008 Mar.
Article in French | MEDLINE | ID: mdl-18374856

ABSTRACT

BACKGROUND: Since congenital rubella has become extremely uncommon following the introduction of rubella vaccination, cutaneous signs are currently rarely reported. PATIENTS AND METHODS: An infant, presenting congenital rubella (seroconversion of the mother for rubella at 11 weeks' amenorrhoea), presented diffuse exanthema between the ages of seven and 24 months. In a setting of congenital rubella syndrome, the infant presented psychomotor retardation, deafness, hypoplasia of the pulmonary artery and under-nourishment. Humoral and cell-mediated immunodeficiency was also noted. DISCUSSION: The cutaneous signs of congenital rubella were first described in the 1960s and 1970s; they are rare and appear after a symptom-free period before resolving spontaneously several months later. Standard findings include chronic exanthema of the face and extremities associating reticulated erythema and pigmented macular papules. Exanthema indicates chronic and persistent viral infection, a common situation in newborn babies and infants following maternal-foetal infection. The persistence of viral infection in infants is attributed to immature cellular immunity, which would otherwise either eradicate the virus or ensure passage to the latency phase. In the present case, there was also relative humoral immunodeficiency resulting from foetal rubella infection. The symptom-free interval before the onset of rash and other clinical signs may be due to the relative transient protection afforded by the presence of maternal immunoglobulines G.


Subject(s)
Exanthema/complications , Pregnancy Complications/virology , Rubella Syndrome, Congenital/complications , Rubella/transmission , Deafness/complications , Female , Humans , Immunologic Deficiency Syndromes/complications , Infant , Pregnancy , RNA, Viral/isolation & purification
16.
Arch Pediatr ; 14 Suppl 3: S194-6, 2007 Oct.
Article in French | MEDLINE | ID: mdl-17961815

ABSTRACT

The rotavirus is the major cause of infantile gastroenteritis worldwide. In Europe and in industrialized countries, rotavirus infections bring out considerable economic expenses. In France, the burden of health expenses is particularly marked during winter period, the peak of rotavirus infections coinciding with that of the respiratory syncitial virus bronchiolitis, this specificity results in an increase of nosocomial infections during this period and a saturation of beds in paediatric hospitals. Vaccination likely represents the only efficacious adapted response to rotavirus infections. Two vaccines have recently been developed and licensed in France. The development of these two vaccines has followed two different strategies. Despite their differences, these vaccines are both safe and efficient in protecting young infants against severe rotavirus acute gastroenteritis. French Health Authorities decided to postpone rotavirus vaccination for at least two years. According scientific and economic data, the French Speaking Group of Gastroenterology Hepatology and Nutrition disagrees with this decision and states that rotavirus vaccination is universally recommended for healthy infants under six months.


Subject(s)
Diarrhea, Infantile/virology , Gastroenteritis/virology , Rotavirus Infections/prevention & control , Rotavirus Vaccines , Vaccination , Diarrhea, Infantile/prevention & control , France , Gastroenteritis/prevention & control , Humans , Infant
17.
Can J Gastroenterol ; 20(7): 475-8, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16858500

ABSTRACT

BACKGROUND: Liver disease is the third most common cause of death in children with cystic fibrosis (CF). Liver transplantation is an effective treatment in children with hepatic failure. AIMS: The objective of the present study was to review the indications and postoperative course of hepatic transplantation in a cystic fibrosis population. PATIENTS: Five children with CF, at a mean age of 16.5 years, underwent liver transplantation. RESULTS: All patients showed cirrhosis, portal hypertension and hepatic failure. The main postoperative complication was ascites refractory to treatment in two patients. No significant deterioration of the pulmonary function was noted. Two patients died, one of Hodgkin lymphoma and the other of progressive pulmonary failure. CONCLUSION: Liver transplantation was indicated in children with CF when hepatic failure and/or severe portal hypertension was present with well-preserved pulmonary function.


Subject(s)
Cystic Fibrosis/complications , Liver Cirrhosis/surgery , Liver Transplantation , Cystic Fibrosis/physiopathology , Female , Humans , Hypertension, Portal/etiology , Immunosuppressive Agents/therapeutic use , Infant , Infant, Newborn , Length of Stay , Liver Cirrhosis/etiology , Male , Postoperative Complications/epidemiology , Respiratory Function Tests
18.
Arch Pediatr ; 12(8): 1221-5, 2005 Aug.
Article in French | MEDLINE | ID: mdl-16051075

ABSTRACT

AIM: To study fecal elastase-1 (E1F) and chymotrypsin (ChT) in stools for the diagnosis of pancreatic insufficiency in pediatric practice. MATERIALS AND METHODS: E1F and ChT were measured in stools of 198 children divided in 3 groups: 49 children without any digestive disease (group A), 71 children with pancreatic diseases (group B), and 78 children with non-pancreatic digestive diseases (group C). RESULTS: In group B, E1F values were very low in 64 children and normal in 7 children without pancreatic insufficiency (6 children with cystic fibrosis and 1 with chronic pancreatitis). ChT values were normal in children without pancreatic insufficiency but also in half of children treated with pancreatic enzymes. Decreased E1F values were seen in 2 children (4%) in the group A and 22 children (28%) in the group C, especially those with acute gastroenteritis or celiac disease. CONCLUSION: E1F is a simple, non-invasive, useful tool for the diagnosis of pancreatic insufficiency in children with growth failure or chronic diarrhea, and those with cystic fibrosis. Nevertheless, low values may be found in diseases with villous atrophy or very liquid stools.


Subject(s)
Exocrine Pancreatic Insufficiency/diagnosis , Feces/enzymology , Pancreatic Elastase/analysis , Adolescent , Biomarkers/analysis , Child , Child, Preschool , Chymotrypsin/analysis , Female , Humans , Infant , Infant, Newborn , Male , Pancreatic Function Tests
20.
Acta Paediatr ; 92(3): 395-7, 2003.
Article in English | MEDLINE | ID: mdl-12725559

ABSTRACT

UNLABELLED: Recurrent abdominal pain (RAP) is generally thought to be of psychological origin but organic aetiologies are increasingly being identified. The cases of two children with vertebral disorders revealed by recurrent abdominal pain are reported. A 14-y-old girl presented with RAP associated with scoliosis, due to a T8-T9 intra-dural extra-medullary tumour. A 7-y-old girl who suffered from nocturnal RAP located in the right iliac fossa for 1 y had decreased muscular strength, pyramidal signs, and a 10 degree Lassègue sign in the right lower limb, revealing a vascular malformation extending from T12 to L2. CONCLUSION: Atypical pain and associated neurological signs or scoliosis must raise the possibility of intra-rachidian disorders. Magnetic resonance examination will then precisely state the location and nature of the pathological process, avoiding excessive delay in therapeutic management.


Subject(s)
Abdominal Pain/diagnosis , Abdominal Pain/etiology , Arteriovenous Malformations/complications , Arteriovenous Malformations/diagnosis , Neurilemmoma/complications , Neurilemmoma/diagnosis , Scoliosis/complications , Scoliosis/diagnosis , Spinal Diseases/complications , Spinal Diseases/diagnosis , Spinal Neoplasms/complications , Spinal Neoplasms/diagnosis , Abdominal Pain/therapy , Adolescent , Arteriovenous Malformations/therapy , Child , Female , Humans , Neurilemmoma/therapy , Recurrence , Scoliosis/therapy , Spinal Diseases/therapy , Spinal Neoplasms/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...